Serveur d'exploration SRAS - Exploration (Accueil)

Index « KwdFr.i » - entrée « Protéines virales (antagonistes et inhibiteurs) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Protéines virales (analyse) < Protéines virales (antagonistes et inhibiteurs) < Protéines virales (biosynthèse)  Facettes :

List of bibliographic references indexed by Protéines virales (antagonistes et inhibiteurs)

Number of relevant bibliographic references: 99.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000991 (2020) Abdo A. ElfikyAnti-HCV, nucleotide inhibitors, repurposing against COVID-19
000B18 (2019) Seri Jo ; Suwon Kim ; Dong Hae Shin ; Mi-Sun KimInhibition of SARS-CoV 3CL protease by flavonoids
000B45 (2019) Kouji Ohnishi [Japon] ; Yasunao Hattori [Japon] ; Kazuya Kobayashi [Japon] ; Kenichi Akaji [Japon]Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
000C59 (2018) Luca Sancineto [Pologne] ; Nunzio Iraci [Italie] ; Oriana Tabarrini [Italie] ; Claudio Santi [Italie]NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors.
000E50 (2017) Li Wang [République populaire de Chine] ; Bo-Bo Bao [République populaire de Chine] ; Guo-Qing Song [République populaire de Chine] ; Cheng Chen [République populaire de Chine] ; Xu-Meng Zhang [République populaire de Chine] ; Wei Lu [République populaire de Chine] ; Zefang Wang [République populaire de Chine] ; Yan Cai [République populaire de Chine] ; Shuang Li [République populaire de Chine] ; Sheng Fu [République populaire de Chine] ; Fu-Hang Song [République populaire de Chine] ; Haitao Yang [République populaire de Chine] ; Jian-Guo Wang [République populaire de Chine]Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study
000F72 (2016) Amira S. Abd El-All [Égypte] ; Sanaa M Sh Atta [Égypte] ; Hanaa M F. Roaiah [Égypte] ; Enas M. Awad [Égypte] ; Mohamed M. Abdalla [Égypte]New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
001053 (2016) Hiroyuki Konno [Japon] ; Masaki Wakabayashi [Japon] ; Daiki Takanuma [Japon] ; Yota Saito [Japon] ; Kenichi Akaji [Japon]Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease
001105 (2016) Kenta Teruya [Japon] ; Yasunao Hattori [Japon] ; Yasuhiro Shimamoto [Japon] ; Kazuya Kobayashi [Japon] ; Akira Sanjoh [Japon] ; Atsushi Nakagawa [Japon] ; Eiki Yamashita [Japon] ; Kenichi Akaji [Japon]Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza‐decaline scaffold
001213 (2015) Kai-Wen Cheng [Taïwan] ; Shu-Chun Cheng [Taïwan] ; Wei-Yi Chen [Taïwan] ; Min-Han Lin [Taïwan] ; Shang-Ju Chuang [Taïwan] ; I-Hsin Cheng [Taïwan] ; Chiao-Yin Sun [Taïwan] ; Chi-Yuan Chou [Taïwan]Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus.
001269 (2015) Michael Berry [Afrique du Sud] ; Burtram C. Fielding [Afrique du Sud] ; Junaid Gamieldien [Afrique du Sud]Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.
001289 (2015) Sakshi Tomar ; Melanie L. Johnston [États-Unis] ; Sarah E. St John ; Heather L. Osswald [États-Unis] ; Prasanth R. Nyalapatla [États-Unis] ; Lake N. Paul ; Arun K. Ghosh [États-Unis] ; Mark R. Denison [États-Unis] ; Andrew D. Mesecar [États-Unis]Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
001297 (2015) Hyun Lee [États-Unis] ; Hao Lei [États-Unis] ; Bernard D. Santarsiero [États-Unis] ; Joseph L. Gatuz [États-Unis] ; Shuyi Cao [États-Unis] ; Amy J. Rice [États-Unis] ; Kavankumar Patel [États-Unis] ; Michael Z. Szypulinski [États-Unis] ; Isabel Ojeda ; Arun K. Ghosh [États-Unis] ; Michael E. Johnson [États-Unis]Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
001307 (2015) Michael Berry [Afrique du Sud] ; Burtram Fielding [Afrique du Sud] ; Junaid Gamieldien [Afrique du Sud]Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies.
001563 (2014) K B Wong [Hong Kong] ; D C C. Wan [Hong Kong] ; H F Chow [Hong Kong]Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease.
001594 (2014) C P Chuck [Hong Kong] ; Z H Ke [Hong Kong] ; C. Chen [Hong Kong] ; D C C. Wan [Hong Kong] ; H F Chow [Hong Kong] ; K B Wong [Hong Kong]Profiling of substrate-specificity and rational design of broad-spectrum peptidomimetic inhibitors for main proteases of coronaviruses.
001604 (2014) Yeong Hun Song ; Dae Wook Kim ; Marcus John Curtis-Long ; Heung Joo Yuk ; Yan Wang ; Ningning Zhuang ; Kon Ho Lee ; Kwon Seok Jeon ; Ki Hun ParkPapain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits.
001625 (2014) Silvia Schwarz [République populaire de Chine] ; Daniel Sauter [République populaire de Chine] ; Kai Wang [République populaire de Chine] ; Ronghua Zhang [République populaire de Chine] ; Bing Sun [République populaire de Chine] ; Anastasia Karioti [Italie] ; Anna Rita Bilia [Italie] ; Thomas Efferth [Allemagne] ; Wolfgang Schwarz [République populaire de Chine]Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus.
001652 (2014) Adeyemi O. Adedeji [États-Unis] ; Kamalendra Singh [États-Unis] ; Ademola Kassim [États-Unis] ; Christopher M. Coleman [États-Unis] ; Ruth Elliott [États-Unis] ; Susan R. Weiss [États-Unis] ; Matthew B. Frieman [États-Unis] ; Stefan G. Sarafianos [États-Unis]Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.
001670 (2014) Jian Lei [Allemagne] ; Jeroen R. Mesters [Allemagne] ; Christian Drosten [Allemagne] ; Stefan Anemüller [Allemagne] ; Qingjun Ma [Allemagne] ; Rolf Hilgenfeld [Allemagne]Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features.
001834 (2013) Zhilin Ren [République populaire de Chine] ; Liming Yan ; Ning Zhang ; Yu Guo ; Cheng Yang ; Zhiyong Lou ; Zihe RaoThe newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
001850 (2013) Hyun Lee [États-Unis] ; Shuyi Cao ; Kirk E. Hevener ; Lena Truong ; Joseph L. Gatuz ; Kavankumar Patel ; Arun K. Ghosh ; Michael E. JohnsonSynergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i -k "Protéines virales (antagonistes et inhibiteurs)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i  \
                -Sk "Protéines virales (antagonistes et inhibiteurs)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdFr.i
   |clé=    Protéines virales (antagonistes et inhibiteurs)
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021